Polydex with phenylephrine, spray 15 ml

The combined preparation for topical application in otorhinolaryngology.

The therapeutic effect of Polydexa with phenylephrine is due to the anti-inflammatory effect of dexamethasone on the nasal mucosa, vasoconstrictor effect of phenylephrine and antibacterial action of antibiotics neomycin and polymyxin B.

When the above antibiotics are combined they broaden the spectrum of antibacterial action against the majority of Gram-positive and Gram-negative microorganisms causing infectious and inflammatory diseases of the nasal cavity and accessory sinuses.

Indications

Infectious and inflammatory diseases of the nasal cavity, pharynx, paranasal sinuses:

acute and chronic nasopharyngitis;
acute and chronic rhinitis;
sinusitis.

Pharmacological effect

Combined drug for local use in otorhinolaryngology.

The therapeutic effect of the drug Polydex with phenylephrine is due to the anti-inflammatory effect of dexamethasone on the nasal mucosa, the vasoconstrictor effect of phenylephrine and the antibacterial effect of the antibiotics neomycin and polymyxin B.

When combining these antibiotics, the spectrum of antibacterial action expands on most gram-positive and gram-negative microorganisms that cause infectious and inflammatory diseases of the nasal cavity and paranasal sinuses.

Special instructions

The drug is not prescribed to patients with renal failure.

Do not use for rinsing the paranasal sinuses.

The drug should be used with caution in patients with arterial hypertension, coronary artery disease, and hyperthyroidism.

It should be borne in mind that the drug contains components that can give a positive result during doping control in athletes.

Active ingredient

Dexamethasone, Neomycin, Polymyxin B, Phenylephrine

Composition

15 ml spray contains:

Active substances:

neomycin sulfate 1g, which corresponds to 650,000 IU;

polymyxin B sulfate 1,000,000 IU;

dexamethasone sodium metasulfobenzoate 0.025 g;

phenylephrine hydrochloride 0.250 g;

Excipients:

methylparaben,

lithium chloride,

citric acid,

lithium hydroxide,

macrogol 400,

polysorbate 80,

purified water q.s. up to 100 ml

Pregnancy

Polydexa with phenylephrine is contraindicated during pregnancy, lactation and children under 2 years of age.

Contraindications

simultaneous use of monoamine oxidase inhibitors;
suspicion of angle-closure glaucoma;
viral diseases;
kidney diseases accompanied by albuminuria;
pregnancy;
breastfeeding period;
children’s age (up to 2.5 years);
hypersensitivity to the components of the drug.

Side Effects

Allergic reactions: rarely – skin manifestations.

Interaction

Drug interactions are due to the content of phenylephrine.

With the simultaneous use of guanethidine and drugs of this group, the hypertensive effect of phenylephrine is enhanced and, due to the decrease in sympathetic tone by guanethidine, prolonged mydriasis is possible.

If such a combination cannot be avoided, then medical supervision is necessary.

Overdose

Due to the low degree of absorption into the systemic circulation, an overdose is unlikely.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Sofartex, France